Ricevi le ultime notizie sulle azioni Astellas Pharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ALPMY

Ultime notizie per

ASTELLAS PHARMA INC

Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Biotech

Large Cap

News

Health Care

General

ALPMF

ALPMY

Nuove prospettive terapeutiche emergono da una ricerca clinica, aprendo orizzonti inattesi nella lotta contro questa aggressiva neoplasia.

Carcinoma uroteliale: studio EV-302 Pfizer/Astellas mostra progressi

ASTELLAS PHARMA UNSP/ADR by Astellas Pharma, Inc.

Astellas Pharma Inc

Press Releases

Notice of Nominees for Directors

Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"

Astellas Announces Top Management Personnel Change

Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025

TYO:4503

Astellas Pharma

Comments

Astellas Pharma Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO